Researchers conducted a randomized controlled trial to assess the effectiveness of a new drug to reduce severe cutaneous reactions in patients with rheumatoid arthritis who are treated with adalimumab. Of 150 adults with rheumatoid arthritis who are treated with adalimumab, 75 received the new drug in addition to adalimumab, and 75 received a placebo in addition to adalimumab. Results show that 6 patients in the new drug group developed severe cutaneous reactions, compared to 9 in the placebo group. Which of the following represents the relative risk reduction for severe cutaneous reactions among patients in the new drug group?
A) 0.08
B) 0.10
C) 0.12
D) 0.33
E) 0.67
Correct Answer:
Verified
Q34: A large study of serum folate levels
Q35: The aim of a case-control study is
Q36: A study was conducted to assess the
Q37: A study is conducted to assess the
Q38: A group of psychiatrists conducts a double-blind placebo-controlled
Q40: An intern in the endocrinology department is
Q41: The population pyramid of a certain country
Q42: A study is conducted to estimate the
Q43: A research laboratory develops a new serologic
Q44: A genome-wide association study (GWAS) of rheumatoid
Unlock this Answer For Free Now!
View this answer and more for free by performing one of the following actions
Scan the QR code to install the App and get 2 free unlocks
Unlock quizzes for free by uploading documents